Oncotelic Therapeutics, Inc. (OTLC) Form 10-Q — May 14, 2026
Oncotelic Therapeutics reported a net loss of $2.2 million for the three months ended March 31, 2026, driven by $1.85 million in operating expenses and $295,000 in interest expense. The company ended the quarter with only $83,614 in cash and negative working capital of $16.3 million, signaling severe liquidity constraints. The filing includes explicit going-concern language, stating that substantial doubt exists about the company's ability to continue as a going concern for the next 12 months. Management acknowledges the need to raise additional capital through equity or debt offerings to remain viable, noting that current cash resources are insufficient.
Key figures
- Eps
- 0
- Cash Position
- 83614
- Operating Loss
- 1853385
- Interest Expense
- 295811
- Shares Outstanding
- 444497302
- Derivative Liability
- 440124
- Convertible Debt Current
- 12519351
- Stock Based Compensation
- 1641847
- Contingent Consideration
- 2625000
- Convertible Debt Long Term
- 1789509
Price after filing
Close on the filing date to close N calendar days later (from $0.05). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.